Press Releases 2015

Dengvaxia® First Dengue Vaccine Approved in Brazil

Sanofi Submits New Drug Application for the Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

Sanofi Pasteur's Dengue Vaccine Approved in the Philippines

Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap : Sanofi Would Become a Global Leader in Consumer Healthcare and Boehringer Ingelheim Would Become Second largest Anima...

Sanofi: Dengvaxia®, World's First Dengue Vaccine, Approved in Mexico

Sanofi: First Doses of Injectable Polio Vaccine ShanIPV(TM) Soon Available for Indian Infants

Sanofi and Regeneron Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® (alirocumab) Injection Fully Enrolled

Sanofi and AstraZeneca Exchange More Than 200,000 Chemical Compounds

Sanofi Announces Commitment to COP21

Xavier Darcos appointed President of the Sanofi Espoir Foundation

Sanofi Pasteur Reveals its Research on a "Universal" Influenza Vaccine

Sanofi and Regeneron Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting

Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes

Sanofi Sets Out Strategic Roadmap for Long-term Growth

Sanofi and Hanmi Announce License Agreement To Develop Portfolio of Long-Acting Diabetes Treatments

Sanofi and the Institut Pasteur reward four researchers for their major contributions in the service of health

Sanofi and BioNTech Announce Cancer Immunotherapy Collaboration and License Agreement

Sanofi grew sales and business EPS(1) in Q3 2015

Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme's Lemtrada® (alemtuzumab) in Clinical Trials

Sanofi: New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis

Sanofi: Genzyme Opts into Alnylam's ALN-AT3 Hemophilia Program for Development and Commercialization Outside of North America and Western Europe

Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

Sanofi Reaches Patent Settlement on Lantus® SoloSTAR®

Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Sanofi's CSR Achievements Recognized in the Dow Jones Sustainability Indices

Sanofi successfully prices EUR 2.0 billion bond issue

Sanofi Reports Positive Top-Line Results in Second Pivotal LixiLan Phase III Study

Sanofi and Regeneron Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC Congress 2015

Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes

Sanofi, Evotec and Apeiron Biologics Enter Collaboration To Develop Novel Small Molecule Immuno-Oncology Treatments

Sanofi, Evotec Enter New Research Collaboration to Discover and Develop Novel Diabetes Therapies

Sanofi : Online Availability of Sanofi Group's Half-Year Financial Report for 2015

Sanofi delivers solid sales and business EPS(1) growth in Q2 2015

Sanofi Announces that First LixiLan Phase III Study Met Primary Endpoint

Sanofi and Regeneron Launch Major New Immuno-Oncology Collaboration

New England Journal of Medicine Publishes New Analyses Confirming that Sanofi Pasteur's Vaccine Candidate Safely Protects Pre-Adolescents to Adults Against Dengue

Sanofi: Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa® (vandetanib) from AstraZeneca

Sanofi and Regeneron Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients

Sanofi and Regeneron Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

Sanofi Announces New, Global Business Unit Structure to Drive Future Growth

Sanofi: Merial Introduces Oravet® Dental Hygiene Chews for Dogs

Sanofi and Regeneron Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

Sanofi Extends Collaboration with Medicines for Malaria Venture to Fight One of the World's Deadliest Parasitic Diseases

Sanofi's New Basal Insulin Lantus® XR, Known as Toujeo® in the U.S. and Europe, Approved in Japan for the Treatment of Diabetes Mellitus

Sanofi Signs a Global Agreement with SUEZ environnement To Enhance Water and Waste Management

FDA Advisory Committee Recommends Approval of Sanofi and Regeneron's Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia

Sanofi's Lyxumia® (lixisenatide) Demonstrated Cardiovascular Safety in People with Type 2 Diabetes and High CV Risk

Sanofi Announces Positive Results for Toujeo® in Phase III Study Extension in Japanese People with Uncontrolled Diabetes

Sanofi: FDA Grants Breakthrough Therapy Designation for Genzyme's Olipudase Alfa

Sanofi Hosts German Chancellor Angela Merkel at Frankfurt Site

Sanofi Appoints Suresh Kumar to the Executive Committee and Executive Vice President, External Affairs

Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis

Sanofi and Regeneron Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference

Sanofi: Annual General Shareholder Meeting of May 4, 2015

Sanofi delivers Q1 2015 Business EPS(1) growth of 2.6% at CER(2) and 12.8% on a reported basis

Sanofi: Toujeo® Approved in the European Union for the Treatment of Diabetes in Adults

Sanofi: FDA Grants Fast Track Designation to Genzyme's Investigational Substrate Reduction Therapy for the Treatment of Fabry Disease

Sanofi: Effect of Genzyme's Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain Atrophy and MRI Lesion Activity Maintained Through Four Years

Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide)

Sanofi: Shantha will provide up to 37 million doses of Shan5(TM)

Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine

Sanofi: Filing of the 2014 U.S. Form 20-F and French "Document de Référence" containing the Annual Financial Report

Sanofi Appoints Robert Castaigne as Audit Committee Chairman

Toujeo® Receives Positive Opinion from the European Regulatory Authorities

Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo®

Sanofi : Sanofi Appoints Olivier Brandicourt as Chief Executive Officer

Sanofi: Sanofi and Lead Pharma to Develop Treatments for Autoimmune Diseases

Sanofi : ENGAGE Randomized Clinical Trial Evaluating Cerdelga® (eliglustat) for Treatment-Naïve Patients with Gaucher Disease Type 1 Published in The Journal of the American Medical Association

Sanofi: Sanofi delivers Business EPS(1) growth of 7.3% at CER in 2014

Sanofi : Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S.

Sanofi : Sanofi and Regeneron Announce Praluent(TM) (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA

Sanofi : European Commission Grants Marketing Authorization for Cerdelga® (eliglustat), Genzyme's Oral Therapy for Gaucher Disease Type 1

SANOFI : Merial receives European approval for chewable NexGard® Spectra(TM)

Sanofi :Sanofi Enters Strategic Manufacturing Collaboration with Boehringer Ingelheim To Produce Biologics

Sanofi : Sanofi, Regeneron: PraluentTM (alirocumab) Marketing Authorization Application Accepted for Review by EMA

Sanofi : Sanofi and Regeneron Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia